Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

Queen's University (Kingston, Ontario)

$135,557.00

Blocking RA Metabolism: A safer approach to retinoid therapy in skin disease

EF 2011-12

Résumé
Topical and oral administration of vitamin A or vitamin A-like drugs are often used in the treatment of skin disorders including severe acne. This treatment however can carry significant risks and side effects due to the broad range of effects of these drugs, and can be particularly harmful if taken during pregnancy. We propose to develop a safer method of treating these disorders by increasing local levels of vitamin A in the skin. We will do this by developing drugs that can inhibit the metabolic breakdown of vitamin A in skin cells, thereby allowing those cells to benefit from the helpful effects of vitamin A treatment, without the risk of adverse side effects.
Programme
Proof of Principle Program - Phase I
Emplacement
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
240748
Name
Petkovich Martin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Blocking RA Metabolism: A safer approach to retinoid therapy in skin disease
Programtype2
Operating Grants
Orgnameinp2
Queen's University (Kingston, Ontario)
Cihramount2
$135,557
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Cyp26; Dermatology; Drug Development; Metabolism; Retinoic Acid; Skin
Abstract
Topical and oral administration of vitamin A or vitamin A-like drugs are often used in the treatment of skin disorders including severe acne. This treatment however can carry significant risks and side effects due to the broad range of effects of these drugs, and can be particularly harmful if taken during pregnancy. We propose to develop a safer method of treating these disorders by increasing local levels of vitamin A in the skin. We will do this by developing drugs that can inhibit the metabolic breakdown of vitamin A in skin cells, thereby allowing those cells to benefit from the helpful effects of vitamin A treatment, without the risk of adverse side effects.
Competitiondate
201109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Petkovich, Martin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $135,557~ $0~